From Lab to Mass Production: Smooth Scale-Up of ODF Manufacturing Parameters

Introduction
In ODF (oral dissolvable film) projects, formulations and process parameters validated at the laboratory stage often need to be replicated in pilot and commercial-scale production. However, during scale-up, issues such as reduced film quality, lower yield, and unstable processes can arise. More importantly, if your target markets include supplements and pharmaceuticals, the scaled-up equipment must continue to meet pharmaceutical-grade GMP standards to support product registration and international export.

1. Common Scale-Up Challenges

1. Inconsistent Drying Results
   Differences in duct design and temperature distribution can lead to uneven film surfaces and content uniformity issues.
2. Reduced Coating Precision
   Wide-width coating can cause edge buildup or thinning in the center.
3. Difficult Tension Control
   Longer web paths increase the risk of tension fluctuations, leading to film stretching or deformation.

2. Strategies for Smooth Scale-Up

• Pilot-Scale Bridge Equipment – Before moving to full production, use a pilot machine (such as the MJ150-L) with the same coating and drying principles as the mass-production model to validate scalability.
• Unified Control and Data Systems – Ensure parameters such as temperature, speed, and tension can be traced and replicated across lab, pilot, and mass-production stages.
• Step-by-Step Optimization – Fine-tune critical factors like duct airflow, coating gap, and liquid feed pressure during the pilot phase before scaling up.

3. HUANGHAI’s Scale-Up Advantage

The MJ150-L (pilot-scale) and MJ150 (mass-production) are both pharmaceutical-grade GMP machines:

• Comply with dual standards for supplement and pharmaceutical manufacturing
• Enable seamless parameter transfer to reduce trial-and-error costs during scale-up
• Provide full data recording and export for regulatory and audit requirements

Conclusion

Smooth parameter scale-up not only accelerates time-to-market but also minimizes rework and waste caused by mismatches in process or equipment. Choosing a pharmaceutical-grade scale-up solution ensures long-term compliance and production stability for ODF products in both supplement and pharmaceutical markets.

*Features Huanghai's exclusive patented hot-air drying technology (Patent No. CN201668734U) ensuring uniform bottom-up heating.

---

Frequently Asked Questions

Q: What is the difference between an ODF film and a transdermal patch?

A: Oral Dissolving Films (ODF) are placed on or under the tongue and dissolve within seconds to minutes, delivering APIs directly through the oral mucosa or via swallowing. Transdermal patches adhere to the skin and deliver APIs through the dermal layers into systemic circulation over hours to days. Despite different delivery routes, both are manufactured using similar solvent-cast film coating processes. Huanghai's MJ150 ODF machine supports both applications on a single platform with approximately 2 working days of changeover time.

Q: What production output can I expect from a Huanghai ODF machine?

A: The MJ150 produces 20,000 films/hour at commercial scale. The MJ150-L targets R&D and pilot production at 8,000–10,000 films/hour. For fully integrated lines, pair either machine with the MJF180 automatic cutting and packaging system (11,900 films/hr) or the more affordable EZ320 (9,000 films/hr). A complete MJ150 + MJF180 line can produce over 150 million finished pouches annually on a single-shift basis. Contact us for pricing and configuration details.

Q: What drying technology does Huanghai use for ODF production?

A: Huanghai uses patented gradient hot-air drying (Patent CN201668734U), which applies a smooth progressive temperature drop rather than stepwise oven zones used by competitors. This results in more uniform film thickness, reduced edge curl, and better API distribution across the film web. An optional far-infrared heating module adds 20–30% drying efficiency for solvent-based formulations. This patented drying system is one of the key technical advantages that justifies Huanghai's position as the preferred ODF equipment supplier to Sinopharm, Shanghai Pharma, and Fosun Pharma.

Q: What are the GMP requirements for ODF production equipment?

A: ODF manufacturing equipment must comply with cGMP (21 CFR Parts 210/211) for US market products, and equivalent standards (EU GMP Annex 1, ChGMP) for other markets. Key requirements: material contact surfaces must be 316L stainless steel or equivalent; CIP/SIP capability or documented cleaning validation; data integrity controls meeting ALCOA+ principles (audit trails, access control). Huanghai ODF machines meet these standards—all product contact surfaces use pharmaceutical-grade materials, and the control system includes operator access logs and parameter change records. Request our GMP compliance documentation.

Q: Can Huanghai machines produce stripe-coated or multi-formula ODF films?

A: Yes. Huanghai holds a patent for multi-formula stripe coating (Patent CN117323228A), enabling two different API formulations to be applied side-by-side in a single coating pass. This eliminates the need for multiple coating/drying cycles when producing combination-drug ODF products. Competitors require manual multi-layer coating with drying intervals between each formula. This capability is particularly valuable for fixed-dose combination products (e.g., dual-API ODFs for cardiovascular or CNS indications) where coating efficiency directly impacts production economics.